中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

非肝硬化性门静脉高压症的临床管理现状

徐京杭 于岩岩 徐小元

引用本文:
Citation:

非肝硬化性门静脉高压症的临床管理现状

DOI: 10.3969/j.issn.1001-5256.2022.07.001
基金项目: 

国家科技重大专项 (2017ZX10202202)

利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:徐京杭负责收集资料并撰写文章;于岩岩、徐小元负责最终审阅定稿。
详细信息
    通信作者:

    徐小元,xiaoyuanxu6@163.com

Current status of the clinical management of non-cirrhotic portal hypertension

Research funding: 

National Science and Technology Major Project (2017ZX10202202)

More Information
  • 摘要: 非肝硬化性门静脉高压症并非罕见,其临床管理策略有别于肝硬化性门静脉高压症。按照发病机制和病因的不同,可分为肝前性、肝性和肝后性门静脉高压症,其中肝性可进一步分为窦前性、窦性和窦后性。结合临床表现、影像学与病理学检查及时诊断,并启动相应治疗是临床管理的关键。然而本组疾病异质性强,不易诊断,亟需临床工作者提高对本组疾病的认识,以期提高临床管理水平。

     

  • [1] HE FL, MA L, LI YR, et al. Non-cirrhotic portal hypertension: the highlight of its diagnosis[J]. J Prac Hepatol, 2022, 25(1): 1-4. DOI: 10.3969/j.issn.1672-5069.2022.01.001.

    何福亮, 马琳, 李悦榕, 等. 非肝硬化性门脉高压的临床诊断[J]. 实用肝脏病杂志, 2022, 25(1): 1-4. DOI: 10.3969/j.issn.1672-5069.2022.01.001.
    [2] LASAGNI A, CADAMURO M, MORANA G, et al. Fibrocystic liver disease: novel concepts and translational perspectives[J]. Transl Gastroenterol Hepatol, 2021, 6: 26. DOI: 10.21037/tgh-2020-04.
    [3] WU X, ZHOU C, LUO SQ. Congenital hepatic fibrosis: clinical features of different clinical types in 75 patients[J]. Chin Hepatol, 2014, 19(7): 479-482, 490. https://www.cnki.com.cn/Article/CJFDTOTAL-ZUAN201407002.htm

    吴欣, 周超, 罗生强. 先天性肝纤维化不同分型的临床特征——75例分析[J]. 肝脏, 2014, 19(7): 479-482, 490. https://www.cnki.com.cn/Article/CJFDTOTAL-ZUAN201407002.htm
    [4] HULTCRANTZ M, BJÖRKHOLM M, DICKMAN PW, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study[J]. Ann Intern Med, 2018, 168(5): 317-325. DOI: 10.7326/M17-0028.
    [5] GAVRIILIDIS P, MARANGONI G, AHMAD J, et al. State of the art, current perspectives, and controversies of Budd-Chiari syndrome: a review[J]. J Clin Med Res, 2022, 14(4): 147-157. DOI: 10.14740/jocmr4724.
    [6] de GOTTARDI A, RAUTOU PE, SCHOUTEN J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 399-411. DOI: 10.1016/S2468-1253(19)30047-0.
    [7] de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ - Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
    [8] KRISHNA YR, YACHHA SK, SRIVASTAVA A, et al. Quality of life in children managed for extrahepatic portal venous obstruction[J]. J Pediatr Gastroenterol Nutr, 2010, 50(5): 531-536. DOI: 10.1097/MPG.0b013e3181b6a55d.
    [9] KHANNA R, SARIN SK. Idiopathic portal hypertension and extrahepatic portal venous obstruction[J]. Hepatol Int, 2018, 12(Suppl 1): 148-167. DOI: 10.1007/s12072-018-9844-3.
    [10] AKHAN O, KARAOSMANOGˇLU AD, ERGEN B. Imaging findings in congenital hepatic fibrosis[J]. Eur J Radiol, 2007, 61(1): 18-24. DOI: 10.1016/j.ejrad.2006.11.007.
    [11] CANNELLA R, GIAMBELLUCA D, DIAMARCO M, et al. Congenital cystic lesions of the bile ducts: imaging-based diagnosis[J]. Curr Probl Diagn Radiol, 2020, 49(4): 285-293. DOI: 10.1067/j.cpradiol.2019.04.005.
    [12] KMEID M, LIU X, BALLENTINE S, et al. Idiopathic non-cirrhotic portal hypertension and porto-sinusoidal vascular disease: review of current data[J]. Gastroenterology Res, 2021, 14(2): 49-65. DOI: 10.14740/gr1376.
    [13] ZHAO XY, ZHANG X, WANG TL, et al. Clinical and pathological features of patients with congenital hepatic fibrosis[J]. J Clin Heptaol, 2010, 26(2): 191-193. DOI: 10.3969/j.issn.1001-5256.2010.02.025.

    赵新颜, 张新, 王泰龄, 等. 先天性肝纤维化14例临床病理特点[J]. 临床肝胆病杂志, 2010, 26(2): 191-193. DOI: 10.3969/j.issn.1001-5256.2010.02.025.
    [14] Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association. Expert consensus on diagnosis and treatment of pyrrolidine alkaloids-related sinusoidal obstruction syndrome (2017, Nanjing)[J]. J Clin Hepatol, 2017, 33(9): 1627-1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003.

    中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年, 南京)[J]. 临床肝胆病杂志, 2017, 33(9): 1627-1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003.
    [15] CORBACIOGLU S, TOPALOGLU O, AGGARWAL S. A systematic review and meta-analysis of studies of defibrotide prophylaxis for veno-occlusive disease/sinusoidal obstruction syndrome[J]. Clin Drug Investig, 2022. DOI: 10.1007/s40261-022-01140-y.[Onlineaheadofprint]
    [16] Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.

    中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
  • 加载中
计量
  • 文章访问数:  647
  • HTML全文浏览量:  159
  • PDF下载量:  208
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-05-15
  • 录用日期:  2022-06-16
  • 出版日期:  2022-07-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回